Boston, MA 03/12/2014 (wallstreetpr) – Enzymotec Ltd (NASDAQ:ENZY) has managed to maintain an atmosphere of excitement around it. Improving earnings and solid stock price characterize the story of ENZY since its initial public offering. Recently some hedge funds have seen adjusting their positions in the stock. So then, can you mimic these hedge funds? We take a look at the funds which have recently adjusted their holding in the stock, but just before doing that, here is a recap of the stock performance in the past hours.
Shares of Enzymotec Ltd (NASDAQ:ENZY) opened Wednesday session at $27.49. As of 10 a.m. EDT the stock was changing hands at $27.83, having already registered gain in the region of $1.91 percent. In the past 12 months, the shares have been changing hands in the range of $14.25 – $35.12. Generally, the shares have not looked back since IPO in September 2013 at the price of $14.
Bullish Hedge Funds
A recent 13G fling reveals that two hedge funds have upped their positions in Enzymotec Ltd (NASDAQ:ENZY). John Paulson who manages Paulson & Co. more than doubled his investment in Enzymotec Ltd (NASDAQ:ENZY). The fund own holds 4.2 million shares, up from 1.7 million shares as per the previous filing. With this fresh position, the fund now owns almost 20 percent of stake in the company; and that stake is worth approximately $112 million.
Yet another bullish hedge fund manager in Enzymotec Ltd (NASDAQ:ENZY) is Jacob Gottlieb of Visium Assets Management. The fund increased its position from the previous 690,000 shares to now 1.14 million shares in the latest filing. Thus, the stake of Visium Assets Management in Enzymotec Ltd (NASDAQ:ENZY) is now 5.2 percent, worth roughly $31 million.
Besides the two hedge funds which have increased their portfolio in the stock of Enzymotec Ltd (NASDAQ:ENZY) in the latest filing, there are also a number of hedge funds holding the stock very closely. These include Springbok Capital which is managed by Gavin Saitowitz whose position is 10,000 shares worth $0.27 million. The other fund is Driehaus Capital by Richard Driehaus whose position is about 83,900 shares with approximate value of $2.27 million.
Investor Takeaway
Enzymotec Ltd (NASDAQ:ENZY) generated $64.98 million in revenue in 2013, almost double $37.87 million for 2012. Analysts estimate earnings per share of 86 cents for the company in the current fiscal year. This number is far beyond the 48 cents that was expected of in 2013. Enzymotec Ltd (NASDAQ:ENZY) is generally a source of good news from its solid stock price to expanding revenue and earnings.
